Filters

Pp-186 manufacturers

Filters

None products found

pp-186

Solution for infusion

Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Third-line (3L) non-small cell lung cancer (NSCLC) — post checkpoint inhibitor (CPI) failure Clinical stage: Phase 3 Modality: Small molecule (telomere-targeting nucleoside analogue) Mechanism / Target: First-in-class telomere-targeting nucleotide; incorporates into cancer cell telomeres generating reactive oxygen species and telomere dysfunction; triggers immunogenic cell death and stimulates anti-tumour immune response; synergises with checkpoint inhibitors Route / form: IV infusion Differentiation: First-in-class telomere-targeting NCE with dual mechanism (direct cytotoxicity + immune activation); Phase 3 THIO-104 initiated Dec 2025 for 3L NSCLC — a population with no approved standard of care; unique mechanism potentiating CPI response;
Manufacturer #39327
US-based clinical-stage immuno-oncology company developing a first-in-class Rx small molecule with a novel mechanism of action. Lead program is in clinical development for a major solid-tumor indication. Listed on a US exchange.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.